Papers/PMID:32730903
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Pharmacological research2020The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
chromium(3+) — decreases fasting blood glucose
Evidence strength: very limited.Findingreplicated ×4“Results revealed significant reduction in FPG (weighted mean difference (WMD): -19.00 mg/dl, 95% CI: -36.15, -1.85, P = 0.030; I2: 99.8%, p < 0.001), insulin level (WMD: -12.35 pmol/l, 95% CI: -17.86, -6.83, P < 0.001), HbA1C (WMD: -0.71 %, 95% CI: -1.19, -0.23, P = 0.004) and HOMA-IR (WMD: -1.53, 95% CI: -2.35, -0.72, P < 0.001; I2: 89.9%, p < 0.001) after chromium supplementation.”
Quoted verbatim from Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with type 2 diabetes, pooled randomized controlled trials
Effect -19 mean difference, 95% CI -36.15 to -1.85
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.2020PMID:3273090310.1016/j.phrs.2020.105098Permalink
chromium(3+) — decreases glycated haemoglobin (HbA1c)
Evidence strength: very limited.Findingreplicated ×2“Results revealed significant reduction in FPG (weighted mean difference (WMD): -19.00 mg/dl, 95% CI: -36.15, -1.85, P = 0.030; I2: 99.8%, p < 0.001), insulin level (WMD: -12.35 pmol/l, 95% CI: -17.86, -6.83, P < 0.001), HbA1C (WMD: -0.71 %, 95% CI: -1.19, -0.23, P = 0.004) and HOMA-IR (WMD: -1.53, 95% CI: -2.35, -0.72, P < 0.001; I2: 89.9%, p < 0.001) after chromium supplementation.”
Quoted verbatim from Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with type 2 diabetes, pooled randomized controlled trials
Effect -0.71 mean difference, 95% CI -1.19 to -0.23
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.2020PMID:3273090310.1016/j.phrs.2020.105098Permalink
chromium(3+) — decreases HOMA-IR
Evidence strength: very limited.Findingreplicated ×2“Results revealed significant reduction in FPG (weighted mean difference (WMD): -19.00 mg/dl, 95% CI: -36.15, -1.85, P = 0.030; I2: 99.8%, p < 0.001), insulin level (WMD: -12.35 pmol/l, 95% CI: -17.86, -6.83, P < 0.001), HbA1C (WMD: -0.71 %, 95% CI: -1.19, -0.23, P = 0.004) and HOMA-IR (WMD: -1.53, 95% CI: -2.35, -0.72, P < 0.001; I2: 89.9%, p < 0.001) after chromium supplementation.”
Quoted verbatim from Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with type 2 diabetes, pooled randomized controlled trials
Effect -1.53 mean difference, 95% CI -2.35 to -0.72
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.2020PMID:3273090310.1016/j.phrs.2020.105098Permalink